ReviewJournal of nanobiotechnology2026
Decoding metabolic diseases through bacterial extracellular vesicles: mechanisms, diagnostics, and therapeutics.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Metabolic diseases represent a class of chronic conditions characterized by disturbances in energy and material metabolism. These diseases primarily include obesity, metabolic dysfunction-associated steatotic liver disease, atherosclerosis, type 2 diabetes, osteoporosis, and polycystic ovary syndrome. A core pathological feature underlying their development is the mutual reinforcement between chronic low-grade inflammation and metabolic imbalance. The gut microbiota has been highlighted by recent research as a key regulator of host metabolism, while bacterial extracellular vesicles (BEVs) are emerging as critical mediators. BEVs transport bioactive molecules (proteins, lipids, nucleic acids) to facilitate microbiota-host crosstalk without direct contact. Pathogen-derived BEVs often exacerbate metabolic dysfunction via inflammation, while commensal/probiotic BEVs protect against disorders by enhancing intestinal barrier function and regulating immunity. Furthermore, owing to their high stability, easy penetration of biological barriers, and capacity to carry abundant cellular information, BEVs demonstrate broad application prospects as non-invasive diagnostic biomarkers for metabolic diseases and as natural or engineered targeted drug delivery vehicles. This review outlines the mechanisms and progress in the application of gut BEVs in metabolic diseases. It aims to deepen our understanding of host-microbiota interaction networks and support the development of novel intervention strategies for metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.